Cipher Pharmaceuticals Inc. (TSE:CPH – Get Free Report) (NASDAQ:CPHR)’s share price was down 18.7% during trading on Wednesday . The stock traded as low as C$13.96 and last traded at C$14.60. Approximately 235,912 shares changed hands during trading, an increase of 768% from the average daily volume of 27,167 shares. The stock had previously closed at C$17.95.
Analyst Upgrades and Downgrades
Separately, Canaccord Genuity Group set a C$17.00 target price on Cipher Pharmaceuticals and gave the stock a “hold” rating in a report on Tuesday, May 12th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of C$17.00.
Check Out Our Latest Stock Report on CPH
Cipher Pharmaceuticals Price Performance
Cipher Pharmaceuticals (TSE:CPH – Get Free Report) (NASDAQ:CPHR) last announced its quarterly earnings results on Tuesday, August 11th. The company reported C$0.21 earnings per share (EPS) for the quarter. Cipher Pharmaceuticals had a return on equity of 22.74% and a net margin of 58.81%.The business had revenue of C$17.14 million for the quarter. On average, sell-side analysts forecast that Cipher Pharmaceuticals Inc. will post 1.2907348 EPS for the current fiscal year.
Cipher Pharmaceuticals Company Profile
Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.
Recommended Stories
- Five stocks we like better than Cipher Pharmaceuticals
- Is Lockheed Martin Gearing Up to Lead Defense Stocks?
- Inside Teledyne’s Bold Bet on the Future of Medical Imaging
- Why Are Analysts Freaking Out About Apple’s All-Glass iPhone?
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
